NASDAQ: VYGRVoyager Therapeutics Inc Stock
$8.48+0.04 (+0.47%)
Updated May 13, 2024
VYGR Price
$8.48
Fair Value Price
N/A
Market Cap
$461.26M
52 Week Low
$6.06
52 Week High
$14.34
P/E
-121.14x
P/B
1.35x
P/S
4.47x
PEG
N/A
Dividend Yield
N/A
Revenue
$119.04M
Earnings
-$3.04M
Gross Margin
100%
Operating Margin
-11.8%
Profit Margin
-2.6%
Debt to Equity
0.38
Operating Cash Flow
$13M
Beta
1.25
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
VYGR Overview
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Zen Score
–
Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how VYGR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VYGR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
VYGR is good value based on its book value relative to its share price (1.35x), compared to the US Biotechnology industry average (6.01x)
P/B vs Industry Valuation
VYGR is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more VYGR due diligence checks available for Premium users.
Be the first to know about important VYGR news, forecast changes, insider trades & much more!
VYGR News
Valuation
VYGR fair value
Fair Value of VYGR stock based on Discounted Cash Flow (DCF)
Price
$8.48
Fair Value
$13.17
Undervalued by
35.63%
VYGR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
VYGR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-121.14x
Industry
7.36x
Market
29.25x
VYGR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.35x
Industry
6.01x
VYGR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
VYGR's financial health
Profit margin
Revenue
$19.5M
Net Income
-$11.3M
Profit Margin
-58.1%
VYGR's Earnings (EBIT) of -$14.05M... subscribe to Premium to read more.
Interest Coverage Financials
VYGR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$469.6M
Liabilities
$128.7M
Debt to equity
0.38
VYGR's short-term assets ($409.14M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VYGR's short-term assets ($409.14M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VYGR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
VYGR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$58.8M
Investing
-$96.1M
Financing
$112.9M
VYGR's operating cash flow ($13.12M)... subscribe to Premium to read more.
Debt Coverage Financials
VYGR vs Biotech Stocks
Voyager Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.